Skip 
Navigation Link
Health Policy & Advocacy
Resources
Basic InformationMore InformationLatest News
ASCO Addresses Cancer Drug PricingHigh Court Rules Against Interstate Medical LiabilityFewer U.S. Dollars Spent on Cardiac Arrest Research: StudyPainkiller Prescriptions More Prone to Errors If HandwrittenFDA Panel OKs What May Soon Be First Gene Therapy Approved in U.S.Walking Rates Are Key to a Country's Obesity LevelsDocs Should Counsel Even Healthy People on Diet, Exercise, Experts SayHealth Service Use Unchanged From 1996-1997 to 2011-2012Easier Colon Exam Boosts Screening, But Insurers May Not PayMore U.S. Patients Are Recording Their Doctor VisitsMedication Mistakes Have Doubled in U.S. Since 2000: StudyPatient Involvement Can Cut Errors in X-Ray ImagingMarket Competition Linked to Change in Generic Drug PricesBlood Shortage Prompts Call for DonationsBullying Takes Financial Toll on U.S. School DistrictsPoll Finds Seniors Struggling With Drug Costs Don't Seek HelpMany U.S. Teens Still Denied 'Morning After' Pill at PharmaciesOlder Americans Struggling With Drug Costs Don't Ask for HelpDoctors Urged to Take Care With Electronic CommunicationsClimate Change Likely to Widen Gap Between Rich, Poor in U.S.: StudyFDA Seeks to Increase Number of Generic Drugs on Market3 Simple Steps Might Reduce Opioid OD DeathsPhysician Attitude Important Factor in Patients Switching PCPMany Adverse Events Related to Cosmetics Go UnreportedStudy Highlights the Beauty Industry's Ugly SideMedicaid Cuts Tied to Delayed Breast Cancer DiagnosesPrimary Care Pharmacy Model Attractive to Patients1991-2014 Saw Minimal Change in Health Spending Per StateLegalized Pot May Lead to More Traffic CrashesMany Doctors Silent on Cost of Cancer CareGroup Urges Tougher Limits on Chemical in Shampoos, Cosmetics18 Percent Increase Projected in Primary Care Demand by 2023Why Patients Leave the Hospital Against Doctor's OrdersRaise the Smoking Age to 21? Most Kids Fine With ThatComprehensive Audiologic Care Feasible in Free Clinic ModelMany Tanning Salons Defy Legal Age Limits on UsersLifesaving Drugs From Pfizer in Short Supply: FDALeading U.S. Doctors' Group Takes Aim at Rising Drug PricesU.S. Hospitals Still Prescribe Too Many Antibiotics: StudyFDA Puts Brakes on Rule Requiring New 'Nutrition Facts' LabelCardiac Arrest? Someday, Drones May Come to Your RescueSAMHSA: 9.8 Million U.S. Adults Have Serious Mental IllnessFDA Asks Maker of Opioid Painkiller Opana ER to Pull Drug From MarketHealth System Sees Success With E-Visits Via Patient PortalOvercharging Common in U.S. Emergency RoomsAdvocating for a Loved OneHigh Costs for Myeloma Patients Not Getting Low-Income SubsidyGetting Bedbugs Out of Nursing Homes, Apartment Buildings - for GoodCosts of ER Treatments a Mystery to Many DocsNew Bill Intends to Repeal Limits on Physician-Owned Hospitals
Questions and AnswersLinksBook Reviews
Related Topics

Health Insurance
Healthcare

High Costs for Myeloma Patients Not Getting Low-Income Subsidy


HealthDay News
Updated: May 31st 2017

new article illustration

WEDNESDAY, May 31, 2017 (HealthDay News) -- There is a substantial financial burden for Medicare beneficiaries with myeloma who do not receive a low-income subsidy (LIS) for orally-administered anticancer therapy, according to a study published online May 25 in the Journal of Clinical Oncology.

Adam J. Olszewski, M.D., from Rhode Island Hospital in Providence, and colleagues identified Part D beneficiaries diagnosed with myeloma in 2007 to 2011. In multivariable models adjusted for sociodemographic and clinical characteristics, the authors analyzed the correlation between LIS and use of immunomodulatory drug (IMiD)-based therapy, delays between IMiD refills, and select health outcomes.

The researchers found that 41 percent of 3,038 beneficiaries received first-line IMiDs. For the first IMiD prescription, the median out-of-pocket cost was $3,178 and $3 for LIS nonrecipients and recipients, respectively; for the first year of therapy the corresponding median costs were $5,623 and $6. LIS receipt correlated with a 32 percent increased probability of receiving IMiDs among beneficiaries aged 75 to 84 years, and, in all groups, with a significantly lower risk of delays between refills (adjusted relative risk, 0.54). There was no significant difference in duration of therapy for LIS recipients and nonrecipients (median, 7.6 months). Significantly fewer emergency department visits and hospitalizations were seen for patients treated with IMiDs versus those receiving bortezomib without IMiDs.

"Medicare beneficiaries with myeloma who do not receive LISs face a substantial financial barrier to accessing orally administered anticancer therapy, warranting urgent attention from policymakers," the authors write.

Several authors disclosed financial ties to the biopharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)